Inhibrx Biosciences, Inc. (INBX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INBX SEC filings page.
Inhibrx Biosciences, Inc. (INBX) reported $1.3M in revenue for fiscal year 2025, up 550.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The development-stage model spends heavily on research, produces little revenue, and relies on financing rather than operations for cash.
Across FY2023-FY2025, revenue remained below$2M while FY2025 R&D was$113.0M ; that gap describes a research program, not a scaled commercial engine. In FY2025, operating cash flow of-$129.8M nearly matched free cash flow of-$129.8M , indicating the cash deficit came from ongoing operations rather than heavy capital spending.
By FY2025, total liabilities of
The operating loss narrowed from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Inhibrx Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Inhibrx Biosciences, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 10/100.
Inhibrx Biosciences, Inc.'s revenue surged 550.0% year-over-year to $1.3M, reflecting rapid business expansion. This strong growth earns a score of 6/100.
Inhibrx Biosciences, Inc. has elevated debt relative to equity (D/E of 12.58), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 3/100, reflecting increased financial risk.
With a current ratio of 3.93, Inhibrx Biosciences, Inc. holds $3.93 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
Inhibrx Biosciences, Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 1/100.
Inhibrx Biosciences, Inc. posts a -1752.2% return on equity (ROE), meaning it loses $1752 for every $100 of shareholders' equity. This results in a returns score of 19/100.
Inhibrx Biosciences, Inc. scores 0.86, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.3B) relative to total liabilities ($138.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Inhibrx Biosciences, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Inhibrx Biosciences, Inc. reported a net loss of $140.1M while operations used $129.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Inhibrx Biosciences, Inc. reported an operating loss of $135.0M against $12.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Inhibrx Biosciences, Inc. generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Inhibrx Biosciences, Inc.'s EBITDA was -$31.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.3% from the same quarter a year earlier. Against the prior quarter it is down 4.1%.
Inhibrx Biosciences, Inc. reported -$36.6M in net income in Q2 2026. This represents a decrease of 27.9% from the same quarter a year earlier. Against the prior quarter it is down 9.6%.
Inhibrx Biosciences, Inc. earned -$2.34 per diluted share (EPS) in Q2 2026. This represents a decrease of 26.5% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.
Cash & Balance Sheet
Inhibrx Biosciences, Inc. recorded an outflow of $29.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 21.3%.
Inhibrx Biosciences, Inc. held $133.3M in cash against $176.3M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Inhibrx Biosciences, Inc. invested $23.9M in research and development in Q2 2026. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.
Not reported for Q2 2026.
INBX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | N/A | N/A | $0 | $1.3M+1200.0% | $0 | N/A | $0-100.0% |
| R&D Expenses | $23.9M+7.3% | $25.2M-31.6% | N/A | $28.5M-26.6% | $22.3M-67.1% | $36.9M-42.2% | N/A | $38.9M+2.2% |
| SG&A Expenses | $8.3M+28.5% | $5.7M-5.2% | N/A | $5.3M-33.2% | $6.4M-93.1% | $6.0M-39.6% | N/A | $7.9M+0.2% |
| Operating Income | -$32.1M-17.4% | -$30.9M+27.9% | N/A | -$33.8M+27.7% | -$27.4M+83.0% | -$42.9M+41.9% | N/A | -$46.8M-2.1% |
| EBITDA | -$31.6M-18.3% | -$30.4M+28.0% | N/A | -$33.2M+27.8% | -$26.7M+83.3% | -$42.2M+42.5% | N/A | -$46.0M-1.1% |
| Interest Expense | $5.7M+81.2% | $3.5M+30.5% | N/A | $3.2M | $3.1M-41.4% | $2.7M-66.9% | N/A | $0-100.0% |
| Income Tax | $3K+50.0% | $0 | N/A | $0 | $2K0.0% | $0 | N/A | $0-100.0% |
| Net Income | -$36.6M-27.9% | -$33.4M+22.8% | N/A | -$35.3M+19.6% | -$28.7M | -$43.3M+45.0% | N/A | -$43.9M+15.3% |
| EPS (Basic) | -$2.34-26.5% | -$2.15+23.2% | -$2.11+58.1% | -$2.28+19.7% | -$1.85-101.5% | -$2.80+51.5% | -$5.03+31.0% | -$2.84+35.3% |
| EPS (Diluted) | -$2.34-26.5% | -$2.15+23.2% | -$2.11+52.8% | -$2.28+19.7% | -$1.85-101.5% | -$2.80+51.5% | -$4.47 | -$2.84+35.3% |
| Diluted Shares (Avg) | 16M+1.3% | 16M+0.8% | N/A | 15M+0.1% | 15M+4.5% | 15M+13.4% | N/A | 15M+31.2% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
INBX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $154.2M-27.3% | $184.0M-24.2% | $146.5M-19.0% | $177.5M-20.3% | $212.1M-17.9% | $242.6M | $180.8M-41.3% | $222.6M |
| Current Assets | $142.2M-26.7% | $171.3M-23.3% | $132.8M-17.2% | $161.4M-22.2% | $194.0M-19.9% | $223.4M | $160.4M-45.7% | $207.4M |
| Cash & Equivalents | $133.3M-28.5% | $161.7M-25.3% | $124.2M-18.6% | $153.1M-22.0% | $186.6M-17.8% | $216.5M-14.2% | $152.6M-45.1% | $196.3M-41.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $207.2M+44.3% | $205.0M+38.3% | $138.5M+193.5% | $140.6M+218.9% | $143.6M+267.6% | $148.2M | $47.2M-82.2% | $44.1M |
| Current Liabilities | $28.1M-27.9% | $26.5M-39.2% | $33.8M-17.0% | $36.0M-18.4% | $38.9M-0.3% | $43.6M | $40.7M-27.7% | $44.1M |
| Non-Current Liabilities | $179.1M+71.2% | $178.5M+70.7% | $104.7M+1522.3% | $104.7M | $104.6M | $104.6M | $6.5M-96.9% | $0 |
| Long-Term Debt | $176.3M+77.6% | $175.0M+77.4% | $100.6M | $99.9M | $99.3M | $98.7M | $0-100.0% | $0 |
| Total Equity | -$53.0M-177.3% | -$21.0M-122.3% | $8.0M-94.0% | $36.8M-79.4% | $68.6M-68.7% | $94.4M+716.4% | $133.6M+207.1% | $178.5M+37.7% |
| Retained Earnings | -$316.3M-77.6% | -$279.6M-87.1% | -$246.2M-132.0% | -$213.4M-266.2% | -$178.1M-1136.5% | -$149.4M | -$106.1M+82.7% | -$58.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
INBX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.9M+0.1% | -$38.0M-5.9% | -$30.1M+31.1% | -$33.8M-11.7% | -$30.0M+47.8% | -$35.9M+43.1% | -$43.7M+23.1% | -$30.3M+44.2% |
| Depreciation & Amortization | $523K-21.0% | $537K-20.4% | $564K-18.1% | $582K-23.4% | $662K+39.4% | $675K+87.5% | $689K+131.2% | $760K+150.0% |
| Stock-Based Compensation | N/A | $2.7M+8.3% | N/A | N/A | N/A | $2.5M-61.7% | N/A | N/A |
| Capital Expenditures | $0 | $0-100.0% | $0-100.0% | $10K-96.0% | $0-100.0% | $21K-98.1% | $16K-99.5% | $247K-69.5% |
| Free Cash Flow | -$29.9M+0.1% | -$38.0M-5.9% | -$30.1M+31.1% | -$33.8M-10.8% | -$30.0M+48.9% | -$35.9M+44.0% | -$43.7M+27.4% | -$30.5M+44.6% |
| Investing Cash Flow | $0 | $0+100.0% | $0+100.0% | -$7K+97.2% | $0+100.0% | -$21K+98.1% | -$16K+99.5% | -$247K+69.5% |
| Financing Cash Flow | $1.6M | $75.5M-24.4% | $1.3M | $352K | $0-100.0% | $99.8M+157.8% | $0-100.0% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
INBX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -2106.8% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -2204.2% | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | -95.7%-71.2pp | -41.8% | -45.9%+634.6pp | N/A | -24.6%+15.4pp |
| Return on Assets | -23.8%-10.3pp | -18.2%-0.3pp | N/A | -19.9%-0.2pp | -13.5% | -17.8% | N/A | -19.7% |
| Current Ratio | 5.07+0.1x | 6.46+1.3x | 3.930.0x | 4.49-0.2x | 4.98-1.2x | 5.12 | 3.94-1.3x | 4.70 |
| Debt-to-Equity | N/A | N/A | 12.58+12.6x | 2.71+2.7x | 1.45+1.4x | 1.04 | 0.00-4.8x | 0.00 |
| Asset Turnover | 0.000.0x | N/A | N/A | 0.000.0x | 0.010.0x | 0.00 | N/A | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | -2304.1% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. INBX | FY2025 | $1.3M | -$140.1M | N/A | $1.3B | 21/100 |
| Astria Therapeutics, Inc. ATXS | FY2024 | N/A | -$94.3M | N/A | $718.1M | — |
| Lexicon Pharmaceuticals, Inc. LXRX | FY2025 | $49.8M | -$50.3M | N/A | $716.4M | 65/100 |
| DiaMedica Therapeutics Inc. DMAC | FY2025 | N/A | -$32.8M | N/A | $421.7M | — |
| Prothena Corporation plc PRTA | FY2025 | $9.7M | -$244.1M | N/A | $429.2M | 55/100 |
| Solid Biosciences Inc. SLDB | FY2025 | N/A | -$174.3M | N/A | $624.1M | — |
Where Inhibrx Biosciences, Inc. Ranks
Frequently Asked Questions
What is Inhibrx Biosciences, Inc.'s annual revenue?
Inhibrx Biosciences, Inc. (INBX) reported $1.3M in total revenue for fiscal year 2025. This represents a 550.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Inhibrx Biosciences, Inc.'s revenue growing?
Inhibrx Biosciences, Inc. (INBX) revenue grew by 550.0% year-over-year, from $200K to $1.3M in fiscal year 2025.
Is Inhibrx Biosciences, Inc. profitable?
No, Inhibrx Biosciences, Inc. (INBX) reported a net income of -$140.1M in fiscal year 2025.
What is Inhibrx Biosciences, Inc.'s EBITDA?
Inhibrx Biosciences, Inc. (INBX) had EBITDA of -$132.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Inhibrx Biosciences, Inc. have?
As of fiscal year 2025, Inhibrx Biosciences, Inc. (INBX) had $124.2M in cash and equivalents against $100.6M in long-term debt.
What is Inhibrx Biosciences, Inc.'s return on equity (ROE)?
Inhibrx Biosciences, Inc. (INBX) has a return on equity of -1752.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Inhibrx Biosciences, Inc.'s free cash flow?
Inhibrx Biosciences, Inc. (INBX) recorded an outflow of $129.8M in free cash flow during fiscal year 2025. This represents a 34.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inhibrx Biosciences, Inc.'s operating cash flow?
Inhibrx Biosciences, Inc. (INBX) recorded an outflow of $129.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Inhibrx Biosciences, Inc.'s total assets?
Inhibrx Biosciences, Inc. (INBX) had $146.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Inhibrx Biosciences, Inc.'s capital expenditures?
Inhibrx Biosciences, Inc. (INBX) invested $31K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Inhibrx Biosciences, Inc. spend on research and development?
Inhibrx Biosciences, Inc. (INBX) invested $113.0M in research and development during fiscal year 2025.
What is Inhibrx Biosciences, Inc.'s current ratio?
Inhibrx Biosciences, Inc. (INBX) had a current ratio of 3.93 as of fiscal year 2025, which is generally considered healthy.
What is Inhibrx Biosciences, Inc.'s debt-to-equity ratio?
Inhibrx Biosciences, Inc. (INBX) had a debt-to-equity ratio of 12.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibrx Biosciences, Inc.'s return on assets (ROA)?
Inhibrx Biosciences, Inc. (INBX) had a return on assets of -95.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inhibrx Biosciences, Inc.'s P/E ratio?
Inhibrx Biosciences, Inc. (INBX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.3B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Inhibrx Biosciences, Inc.'s price-to-sales ratio?
Inhibrx Biosciences, Inc. (INBX) trades at 965x sales, its market capitalization divided by revenue of $1.3M revenue, FY2025. The market capitalization is $1.3B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Inhibrx Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Inhibrx Biosciences, Inc. (INBX) held $124.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $129.8M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Inhibrx Biosciences, Inc.'s Altman Z-Score?
Inhibrx Biosciences, Inc. (INBX) has an Altman Z-Score of 0.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Inhibrx Biosciences, Inc.'s Piotroski F-Score?
Inhibrx Biosciences, Inc. (INBX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibrx Biosciences, Inc.'s earnings high quality?
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $140.1M while operations used $129.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inhibrx Biosciences, Inc. cover its interest payments?
Inhibrx Biosciences, Inc. (INBX) reported an operating loss of $135.0M against $12.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Inhibrx Biosciences, Inc.?
Inhibrx Biosciences, Inc. (INBX) scores 21 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.